Recent Finacing
Recent Raise
Cornerstone Pharmaceuticals is a clinical-stage oncology company developing AEMD metabolic-targeted therapies, including CPI-613 (PDH/KGDH inhibitor), plus Emulsiphan lipid nanoemulsion, evaluated in Phase I/II oncology trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor